We have located links that may give you full text access.
Pure red cell aplasia in cats: 9 cases (1989-1997).
Journal of the American Veterinary Medical Association 1999 January 2
OBJECTIVE: To evaluate clinical features, laboratory test results, treatment, and outcome of FeLV-negative cats with pure red cell aplasia (PRCA) diagnosed by examination of bone marrow.
DESIGN: Retrospective study.
ANIMALS: 9 cats.
PROCEDURE: Medical records and smears of bone marrow aspirates were reviewed to determine clinical features, laboratory test results, treatment, and outcome of this syndrome in cats.
RESULTS: PRCA was diagnosed in 9 cats that were between 8 months and 3 years old. Cats had 2- to 16-day histories of lethargy and anorexia, and a severe normocytic, normochromic to hypochromic, nonregenerative anemia (Hct range, 6 to 15%; reference range, 25 to 45%). Other hematologic values were generally within reference ranges. Consistent changes in biochemical profiles included high aminotransferase activities and hyperferremia. Cats were seronegative for FeLV and feline immunodeficiency virus. Smears of bone marrow aspirates were characterized by absence of identifiable erythroid precursors and a high proportion of small lymphocytes. Abnormalities were not identified in megakaryocytes or myeloid cells. Treatment with immunosuppressive drugs (corticosteroids and cyclophosphamide or cyclosporin) resulted in resolution of anemia within 3 to 5 weeks. Most cats required long-term treatment to maintain Hct within reference range and tended to relapse when treatment frequency or dosage was decreased (especially if done rapidly) or treatment was discontinued.
CLINICAL IMPLICATIONS: PRCA is a rare syndrome in young FeLV-negative cats, and is characterized by severe nonregenerative anemia and absence of erythroid cells in bone marrow. The condition requires prompt, aggressive, often long-term treatment with immunosuppressive drugs for resolution.
DESIGN: Retrospective study.
ANIMALS: 9 cats.
PROCEDURE: Medical records and smears of bone marrow aspirates were reviewed to determine clinical features, laboratory test results, treatment, and outcome of this syndrome in cats.
RESULTS: PRCA was diagnosed in 9 cats that were between 8 months and 3 years old. Cats had 2- to 16-day histories of lethargy and anorexia, and a severe normocytic, normochromic to hypochromic, nonregenerative anemia (Hct range, 6 to 15%; reference range, 25 to 45%). Other hematologic values were generally within reference ranges. Consistent changes in biochemical profiles included high aminotransferase activities and hyperferremia. Cats were seronegative for FeLV and feline immunodeficiency virus. Smears of bone marrow aspirates were characterized by absence of identifiable erythroid precursors and a high proportion of small lymphocytes. Abnormalities were not identified in megakaryocytes or myeloid cells. Treatment with immunosuppressive drugs (corticosteroids and cyclophosphamide or cyclosporin) resulted in resolution of anemia within 3 to 5 weeks. Most cats required long-term treatment to maintain Hct within reference range and tended to relapse when treatment frequency or dosage was decreased (especially if done rapidly) or treatment was discontinued.
CLINICAL IMPLICATIONS: PRCA is a rare syndrome in young FeLV-negative cats, and is characterized by severe nonregenerative anemia and absence of erythroid cells in bone marrow. The condition requires prompt, aggressive, often long-term treatment with immunosuppressive drugs for resolution.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app